| 000 | 01875 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516081451.0 | ||
| 264 | 0 | _c20130429 | |
| 008 | 201304s 0 0 eng d | ||
| 022 | _a1522-9645 | ||
| 024 | 7 |
_a10.1093/eurheartj/ehs042 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGong, Inna Y | |
| 245 | 0 | 0 |
_aClarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. _h[electronic resource] |
| 260 |
_bEuropean heart journal _cNov 2012 |
||
| 300 |
_a2856-2464a p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 |
_aAryldialkylphosphatase _xgenetics |
| 650 | 0 | 4 |
_aBiotransformation _xdrug effects |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C19 |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xdrug effects |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMidazolam _xpharmacokinetics |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlatelet Aggregation _xdrug effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 |
_aPolymorphism, Genetic _xgenetics |
| 650 | 0 | 4 |
_aTiclopidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aCrown, Natalie | |
| 700 | 1 | _aSuen, Colin M | |
| 700 | 1 | _aSchwarz, Ute I | |
| 700 | 1 | _aDresser, George K | |
| 700 | 1 | _aKnauer, Michael J | |
| 700 | 1 | _aSugiyama, Daisuke | |
| 700 | 1 | _aDeGorter, Marianne K | |
| 700 | 1 | _aWoolsey, Sarah | |
| 700 | 1 | _aTirona, Rommel G | |
| 700 | 1 | _aKim, Richard B | |
| 773 | 0 |
_tEuropean heart journal _gvol. 33 _gno. 22 _gp. 2856-2464a |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/eurheartj/ehs042 _zAvailable from publisher's website |
| 999 |
_c21583224 _d21583224 |
||